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Sesamin, a representative sesame lignan, has health promoting activities. Sesamin is converted into 2 
catechol derivatives and further into their glucuronides or sulfates in vivo, whereas the biological 3 
activities of sesamin metabolites remain unclear. We examined the inhibitory effects of sesamin 4 
metabolites on the lipopolysaccharide (LPS)-induced NO production in mouse macrophage-like 5 
J774.1 cells and found that a mono-catechol derivative SC1, (7α,7’α,8α,8’α)-3,4-dihydroxy-3’,4’-6 
methylenedioxy-7,9’:7’,9-diepoxylignane, has a much higher activity than sesamin and other 7 
metabolites. The inhibitory effects of SC1 glucuronides were time-dependently enhanced, 8 
associated with the intracellular accumulation of SC1 and the methylated form. SC1 glucuronides 9 
and SC1 attenuated the expression of the inducible NO synthase (iNOS) and the upstream 10 
interferon-β (IFN-β) in the LPS-stimulated macrophages. The inhibitory effects of SC1 11 
glucuronides against NO production were cancelled by the β-glucuronidase inhibitor and enhanced 12 
by the catechol-O-methyltransferase inhibitor. Our results suggest that SC1 glucuronides exert the 13 
anti-inflammatory effects by inhibiting the IFN-β/iNOS signaling through the macrophage-14 
mediated deconjugation.  15 




Seeds and oils of sesame (Sesamum indicum L.) have long been recognized as traditional 18 
healthy foods in East Asian countries. Sesame seeds are a rich source of various nutrients, such as 19 
lipids, proteins, vitamins and minerals 1, 2. In addition, the non-nutrient lignans in sesame seeds 20 
have attracted significant attention for their contribution to the biological activities and are 21 
commercially available as nutraceuticals in the form of capsules for an antioxidant function. The 22 
major sesame lignans are lipophilic sesamin and sesamolin in sesame oils and hydrophilic 23 
sesaminol glucosides in sesame seed cakes 3.  24 
Sesamin, (7α,7’α,8α,8’α)-3,4:3’,4’-bis(methylenedioxy)-7,9’:7’,9-diepoxylignane, has 25 
been shown to improve the lipid- and alcohol-metabolism 4-8 and have anti-oxidative 9-12, anti-26 
inflammatory 13-15, anti-hypertensive 16-19 and anti-cancer activities 20. Although sesamin has no 27 
anti-oxidative activity in vitro, it has been shown to have an anti-oxidative activity through the 28 
metabolism in liver tissue 9, indicating that sesamin metabolites may contribute to the biological 29 
effects of sesamin in vivo. Most of the ingested sesamin is incorporated into the liver through the 30 
portal vein, then transported to peripheral tissues through the bloodstream. A small amount of 31 
sesamin is delivered to the body through a lymphatic pathway 21. As shown in Figure 1, in the liver, 32 
the methylenedioxyphenyl moiety of sesamin is converted into a dihydrophenyl (catechol) moiety 33 
by the drug metabolizing enzyme cytochrome P450 (CYP450) to generate the monocatechol SC1, 34 
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(7α,7’α,8α,8’α)-3,4-dihydroxy-3’,4’-methylenedioxy-7,9’:7’,9-diepoxylignane, and dicatechol 35 
SC2, (7α,7’α,8α,8’α)-3,4:3’,4’-bis(dihydroxy)-7,9’:7’,9-diepoxylignane. SC1 and SC2 are 36 
partially methylated by catechol-O-methyltransferase (COMT) to generate SC1m, (7α,7’α,8α,8’α)-37 
3-methoxy-4-hydroxy-3’,4’-methylenedioxy-7,9’:7’,9-diepoxylignane, and SC2m, 38 
(7α,7’α,8α,8’α)-3-methoxy-4-hydroxy-3’,4’-dihydroxy-7,9’:7’,9-diepoxylignane. They are further 39 
conjugated by UDP-glucuronosyltransferases (UGT) and sulfotransferases (SULT) to generate the 40 
corresponding glucuronides and sulfates 9, 22-25. 41 
The catechol forms of sesamin metabolites are detected in the β-glucuronidase/sulfatase-42 
treated human plasma, but not in the intact human plasma after the oral intake of capsules 43 
containing sesamin 24, suggesting that sesamin metabolites mostly exist as the conjugates 44 
(glucuronides and sulfates) of the sesamin catechols in the human plasma. Therefore, to understand 45 
the mechanism of action of sesamin in vivo, an investigation about the effects of sesamin 46 
metabolites, especially the conjugates, is essential. Moreover, sesamin catechol conjugates are 47 
expected to be deconjugated into SC1 with a higher reactivity at the inflamed sites because the 48 
neutrophils and macrophages express a β-glucuronidase-like activity especially under the 49 
inflammatory situations 26-28. Although many studies reported the anti-inflammatory effects of 50 
sesamin in vitro and in vivo 13-15, the effects of sesamin metabolites remain to be clarified. In the 51 
present study, we investigated the anti-inflammatory activities and the mechanisms of action of 52 
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sesamin metabolites which related with deconjugation in macrophages.  53 
 54 
MATERIALS AND METHODS 55 
 Chemicals and antibodies.  Sesamin and the metabolites (SC1, SC1m, SC2, SC2m, 56 
SC1-4-O-glucuronide (SC1-4GA), SC1-4-O-sulfate (SC1-4S), SC1-3-O-glucuronide (SC1-3GA) 57 
and SC1-3-O-sulfate (SC1-3S)) (Figure 1) were provided by Suntory Wellness, Ltd. (Kyoto, Japan). 58 
Sesamin and the authentic standards of sesamin metabolites (SC1, SC1m, SC2, and SC2m) were 59 
prepared using the method described previously 9, 29. SC1-4GA, SC1-4S, SC1-3GA and SC1-3S 60 
were synthesized by referring to the methods described previously 30, 31. One hydroxyl group of 61 
SC1 was protected with benzyl group, the other hydroxyl group was glucuronidation or sulfation. 62 
And then, SC1 conjugates were prepared by debenzylation with Pd/C under a hydrogen atmosphere. 63 
The purity of sesamin related compounds is as follows: sesamin (99.3%), SC1 (98%), SC1m 64 
(99.6%), SC2 (97%), SC2m (99%), SC1-4GA (97.6%), SC1-4S (99.8%), SC1-3GA (96.8%) and 65 
SC1-3S (99.3%). D-Saccharic acid 1,4-lactone, and antibodies against iNOS and β-actin were 66 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). LPS from Escherichia coli O127:B8, 67 
sulfanilamide and 3,5-dinitrocatechol were purchased from Sigma-Aldrich (St. Louis, MO). N-1-68 
naphthylethylenediamine dihydrochloride, phosphoric acid and sodium nitrite were purchased 69 
from Wako Pure Chemical Industries, Ltd. (Osaka, Japan) Antibodies against the phospho-70 
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extracellular signaling-regulated kinase 1/2 (ERK1/2) (T202/Y204), ERK1/2, phospho-c-Jun-N-71 
terminal kinase (JNK) (T183/Y185), JNK, p38 mitogen-activated protein kinases (MAPK) and IκB 72 
were purchased from Cell Signaling Technology, Inc. (Beverly, MA). The antibody against 73 
phospho-p38 MAPK (T180/Y182) was purchased from Elabscience Biotechnology, Inc. (Houston, 74 
TX). Fetal bovine serum (FBS) was purchased from Thermo Fisher Scientific (Waltham, MA). The 75 
peroxidase-conjugated goat anti-rabbit and anti-mouse IgG antibodies were purchased from Merck 76 
Millipore (Billerica, MA). All other chemicals were purchased from Nakalai Tesque, Inc. (Kyoto, 77 
Japan).  78 
 Cell culture.  The mouse macrophage-like cell line J774.1 was obtained from the 79 
American Type Culture Collection (Manassas, VA). The J774.1 cells were maintained in 80 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% heat-inactivated FBS, 100 81 
units/mL penicillin and 100 μg/mL streptomycin. Cells were grown at 37 °C under 95% humidified 82 
air and 5% CO2. The passage number of J774.1 used in this study is 3-20.  83 
 Western blot analysis.  Cells grown in a 12-well plate with 80% confluence were treated 84 
with the combination of each sesamin-related compound (25 μM) and LPS (1 μg/mL) in the FBS-85 
free DMEM. Under the pre-treatment conditions, the cells were treated with each SC1 conjugate, 86 
then stimulated with LPS in the new medium. After treatment, the cells were washed with ice-cold 87 
phosphate buffered saline (PBS) and were lysed in a radio-immunoprecipitation assay buffer (50 88 
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mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mM 89 
ethylenediaminetetraacetic acid containing the protease inhibitor cocktail and phosphatase 90 
inhibitor cocktail (Nakalai Tesque, Inc.). After sonication and centrifugation, the supernatant was 91 
used as the protein samples. The protein concentration of the supernatant was determined using the 92 
Protein Assay Bicinchoninate Kit (Nakalai Tesque, Inc.). Equal quantities of the protein were 93 
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a 94 
Hybond-P membrane (GE Healthcare UK, Ltd., Amersham Place, Little Chalfont, England). The 95 
membranes were blocked by EzBlock Chemi (ATTO Corporation, Tokyo, Japan) and incubated 96 
with the primary antibody overnight at 4 °C followed by the appropriate secondary antibody. The 97 
membranes were then treated with Chemi-Lumi One Super to induce the chemiluminescent signals 98 
for the detection of phosphorylated proteins and with Chemi-Lumi One L (Nakalai Tesque, Inc.) 99 
for other proteins, and the signals were detected and visualized using the Ez-Capture MG (ATTO 100 
Corporation).  101 
 Griess assay for the quantification of nitrite.  The Griess reaction system, originally 102 
described by Griess in 1879 as a method of analysis of nitrite analysis, is based on the two-step 103 
diazotization reaction. Briefly, under acidic conditions with phosphoric acid, nitrite reacts with 104 
sulfanilamide to yield a diazonium salt. When coupled with N-1-naphthylethylenediamine, the 105 
diazonium salt forms a red-violet colored, water-soluble azo dye which absorbs light at 540 nm. 106 
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Cells grown in a 24-well plate with 80% confluence were treated with the combination of sesamin-107 
related compounds (10 or 25 μM) and LPS (1 μg/mL) in the phenol red-free and FBS-free DMEM. 108 
Under the pre-treatment conditions, the cells were treated with each SC1 conjugate, then stimulated 109 
with LPS in the new medium. In the experiments, a β-glucuronidase inhibitor D-saccharic acid 1,4-110 
lactone (2 mM) was added to the medium every 8 h to sustain the activity of the unstable D-111 
saccharic acid 1,4-lactone. After incubation, 100 μL of the cell culture supernatant was placed in a 112 
96-well plate and mixed with 50 μL of 1% sulfanilamide in 5% phosphoric acid and 50 μL of 0.1% 113 
N-1-naphthylethylenediamine. The absorbance at 550 nm was measured by a microplate reader 114 
(MTP-800Lab, Hitachi High-Tech Science Corporation, Tokyo, Japan). The nitrite concentration 115 
was determined by comparison with the standard curve of sodium nitrite. 116 
        Analysis for cellular accumulation of sesamin metabolites.  Cells grown in a 60-mm 117 
dish with 80% confluence were treated with SC1 conjugates for 0, 8, 12 and 24 h in FBS-free 118 
medium. The experiments using β-glucuronidase inhibitor were carried out in the same way as 119 
already mentioned. After incubation, the cells were washed five times with PBS and collected by 120 
scraping in a certain amount of methanol. After sonication, an aliquot of the mixture was dissolved 121 
in the solution of Protein Assay Bicinchoninate Kit to measure the protein level. The remaining 122 
was centrifuged at 15000 rpm for 5 min and the supernatant was collected, evaporated, and 123 
dissolved in 100 μL of 50% methanol. Ten μL of the sample was injected into a high-performance 124 
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liquid chromatography-electrochemical detection (HPLC-ECD) system as described below.  125 
 HPLC-ECD.  Samples were injected into an HPLC-ECD system (ESA, Cambridge, 126 
MA) equipped with a COSMOSIL 5C18-AR-II (4.6 ID × 150 mm, Nakalai Tesque, Inc.). The 127 
compound separation was performed using the gradient elution method. Solvent A was 0.5% 128 
phosphoric acid, and solvent B was 100% acetonitrile. The gradient program was as follows: 0-2 129 
min, 25%B; 2-20 min, linear gradient to 80%B; 20-21 min, linear gradient to 100%B; 21-25 min, 130 
hold; 25-25.1 min, 100-25%B; flow rate, 0.8 mL/min. Electrochemical detection was carried out 131 
by the coulometric electrode array system with four electrodes in the array whose potentials were 132 
incrementally set at 200, 300, 400 and 500 mV. Quantification of sesamin metabolites was 133 
performed based on the peak areas of authentic compounds (SC1, SC1m and SC1 conjugates, 134 
Supporting Information Figure S1). 135 
 RNA isolation and real-time reverse transcription-polymerase chain reaction (RT-136 
PCR).  After washing the cells with ice-cold PBS, the total cellular RNA was isolated using 137 
sepazol-RNA I super G (Nakalai Tesque, Inc.) according to the manufacturer’s instructions. The 138 
RNA concentration was determined using the QuantiFluor® RNA System on a QuantusTM 139 
Fluorometer (Promega Corporation, Madison, WI). After reverse transcription into cDNA with a 140 
ReverTra Ace® qPCR RT Master Mix and gDNA remover (TOYOBO CO., LTD., Osaka, Japan), 141 
qPCR was then performed using a LightCycler® Nano real-time PCR system (Roche Diagnostics 142 
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K.K., Tokyo, Japan) with the THUNDERBIRD® SYBR® qPCR Mix (TOYOBO CO., LTD.) and 143 
gene-specific primers. The primers used were as follows: IFN-β, 5’-144 
AGCTCCAAGAAAGGACGAACAT-3’ (forward) and 5’-GCCCTGTAGGTGAGGTTGATCT-3’ 145 
(reverse); GAPDH, 5’-TCAAGCTCATTTCCTGGTAT-3’ (forward) and 5’-146 
GTCCAGGGTTTCTTACTCCT-3’ (reverse). Fold changes of the target gene (IFN-β) expression 147 
were calculated by the comparative Ct method and normalized to the housekeeping gene (GAPDH) 148 
expression.  149 
 Statistical analysis.  The statistical significance was analyzed by a one-way analysis of 150 
variance (ANOVA) followed by multiple comparisons among the means (Tukey’s HSD) using R 151 
software, version 3.4.2. The P values of <0.05 were regarded to be statistically significant. 152 
 153 
RESULTS 154 
 Sesamin metabolites exert an anti-inflammatory effect in J774.1 cells.  To check the 155 
anti-inflammatory activity of sesamin and the metabolites (SC1, SC1m, SC2, SC2m, SC1-4GA, 156 
SC1-4S, SC1-3GA and SC1-3S, Figure 1), we evaluated the inhibitory effects of these compounds 157 
on the NO production in LPS-stimulated J774.1 cells. Upon co-treatment with each compound and 158 
LPS (Figure 2), sesamin weakly inhibited LPS-increased the NO production while SC1 strongly 159 
inhibited. The inhibitory effects of SC1 were attenuated by the methylation, suggesting that the 160 
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catechol group of SC1 seems to contribute to the inhibitory effects. The inhibitory effects of SC2 161 
(dicatechol form) and the methylated form, SC2m, were weaker than that of SC1 (monocatechol 162 
form). On the other hand, SC1 glucuronides (SC1-4GA and SC1-3GA) slightly inhibited the LPS-163 
induced NO production, while SC1 sulfates (SC1-4S and SC1-3S) had no effect.  164 
 SC1 conjugates are time-dependently deconjugated to accumulate in macrophages.  165 
We previously revealed that a glucuronide of quercetin, a catechol-type flavonoid, is deconjugated 166 
by the interaction with macrophages, resulting in the cellular accumulation of quercetin and the 167 
methylated derivative 32. Therefore, we examined the intracellular accumulation of SC1 and SC1m 168 
during the treatment of macrophages with SC1 conjugates. The analysis using HPLC-ECD showed 169 
the accumulation of SC1 and especially SC1m in macrophages treated with SC1 glucuronides in a 170 
time-dependent manner (Figure 3A and Supporting Information Figure S2). On the other hand, 171 
SC1 and SC1m were scarcely detected by the treatment with SC1 sulfates, although SC1 sulfates 172 
themselves were detected. These results indicate that SC1 glucuronides are deconjugated to 173 
accumulate mainly as SC1m in the macrophages and, in contrast, SC1 sulfates are only slightly 174 
deconjugated. 175 
Since the time-dependent accumulation of SC1 and SC1m was observed in macrophages 176 
treated with SC1 conjugates, we examined whether or not the pre-treatment of SC1 conjugates 177 
facilitates their anti-inflammatory activities. As shown in Figure 3B, the inhibitory effects of SC1 178 
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conjugates against the LPS-induced NO production were enhanced by the pre-treatment for 12-24 179 
h when compared to the co-treatment conditions. The inhibitory potency of SC1-3GA was higher 180 
than SC1-4GA and SC1 sulfates scarcely have inhibitory effects, suggesting the correlation 181 
between the anti-inflammatory activities and susceptibility to deconjugation of SC1 conjugates.  182 
 SC1 and SC1 glucuronides inhibit IFN-β and iNOS expression in LPS-stimulated 183 
macrophages.  When LPS, one of the inflammatory stimuli, is recognized by the Toll-like 184 
receptor 4 (TLR4) in macrophages, the multiple signaling pathways are activated, including the 185 
MAPK pathway, nuclear factor-κB (NF-κB) pathway and IFN-β pathway 33. These pathways up-186 
regulate the expression of iNOS to generate the pro-inflammatory mediator NO 34, 35. To elucidate 187 
the molecular mechanisms of the anti-inflammatory effects of SC1 and SC1 conjugates, we 188 
investigated the involvement of these signaling pathways. The co-treatment with SC1 remarkably 189 
suppressed the LPS-induced protein expression of iNOS (Figure 4A, left), while the pre-treatment 190 
with SC1 glucuronides, but not SC1 sulfates suppressed the iNOS expression. In contrast, the 191 
inhibitory effects of the co-treatment with SC1m were not observed (Figure 4A, right). The co-192 
treatment with SC1 slightly suppressed the phosphorylation of p38, but not of ERK and JNK, and 193 
had no effects on the degradation of IκB in the LPS-stimulated macrophages (Figure 4B). On the 194 
other hand, the pre-treatment with SC1 conjugates had little effects on the phosphorylation of ERK, 195 
JNK and p38 and the degradation of IκB in the LPS-stimulated macrophages (Figure 4C). The 196 
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LPS-induced IFN-β mRNA expression was significantly suppressed by the co-treatment with SC1 197 
and pre-treatment with SC1 glucuronides (Figure 4D). These results suggest that the inhibitory 198 
effects of SC1 and the glucuronides on the NO production in the LPS-stimulated macrophages are 199 
mediated by the attenuation of the IFN-β transcription and iNOS protein expression.  200 
 The anti-inflammatory effects of SC1 glucuronides are mediated by the β-201 
glucuronidase activity of the macrophages.  Since the macrophage seems to be mainly 202 
involved in the deconjugation of the glucuronides, we examined the effect of the β-glucuronidase 203 
inhibitor, D-saccharic acid 1,4-lactone, on the cellular accumulation of SC1 and SC1m by treatment 204 
of the macrophages with SC1 conjugates. As shown in Figure 5A and Supporting Information 205 
Figure S3, the treatment of the β-glucuronidase inhibitor dramatically suppressed the cellular 206 
accumulation of SC1 and SC1m in the cells treated with SC1 glucuronides but not affected in the 207 
cells treated with SC1 sulfates. In the preliminary experiment, the supernatant of FBS-free 208 
antibiotics containing medium after the incubation with macrophages for 24 h or the fresh FBS-209 
free antibiotics containing medium is adjusted to acidic condition (pH5.2) suitable for enzyme 210 
reaction by sodium acetate, and then incubated with SC1 glucuronides for 1 h at 37 °C in a cell-211 
free system. As the result, SC1 conjugates were deconjugated by the incubation with the cell culture 212 
supernatant of the macrophages, but not with fresh medium (data not shown), suggesting the 213 
contribution of the secretion with β-glucuronidase activity from macrophages to the deconjugation 214 
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of SC1 glucuronides. These results indicate that the β-glucuronidase activity of the macrophage is 215 
essential for the accumulation of SC1 and SC1m in the cells treated with SC1 glucuronides.  216 
Next, we examined the role of the β-glucuronidase activity in the anti-inflammatory 217 
effects of SC1 conjugates. The β-glucuronidase inhibitor completely impaired the inhibitory effects 218 
of SC1 glucuronides on the LPS-induced NO production (Figure 5B), suggesting that SC1 219 
glucuronides elicit the anti-inflammatory effects through the deconjugation by the β-glucuronidase 220 
activity of the macrophage. 221 
 The cellular accumulation of SC1m induced by the treatment of SC1 glucuronides is 222 
mediated by the COMT activity of the macrophages.  SC1 glucuronides are metabolized to 223 
accumulate mainly as SC1m in the macrophages, suggesting the involvement of COMT as well as 224 
the β-glucuronidase activity of the macrophages. Thus, we examined the effect of the COMT 225 
inhibitor, 3,5-dinitrocatechol, on the accumulation of SC1m and SC1 in the macrophages treated 226 
with SC1 conjugates. The cellular accumulation of SC1m was counteracted by the co-treatment of 227 
the COMT inhibitor accompanied with the increase in SC1 cellular accumulation (Supporting 228 
Information Figure S4). Since the anti-inflammatory effect of SC1 was stronger than that of SC1m 229 
(Figure 2), we expected that the inhibition of the COMT activity facilitates the anti-inflammatory 230 
activity of SC1 glucuronides. As expected, the inhibitory effects of SC1 glucuronides are 231 
significantly enhanced by the co-treatment of the COMT inhibitor and the effects are comparable 232 
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to SC1 (Figures 5C and 2). These results indicate that during the macrophage-mediated metabolic 233 
conversion of SC1 glucuronides into SC1 and SC1m, SC1 could act as the active form for the anti-234 
inflammatory effects.  235 
 236 
DISCUSSION 237 
Sesamin, one of the major sesame lignans, is known to have numerous physiological 238 
effects related to health promotion. Since sesamin has an anti-oxidative activity in vivo but not in 239 
vitro 9, sesamin metabolites are expected to play important roles in the biological effects of sesamin. 240 
Orally-ingested sesamin in humans and rodents is absorbed and metabolized into various 241 
derivatives that circulate in the blood stream 24, 25. Thus, to understand the molecular mechanisms 242 
underlying the physiological effects of sesamin in vivo, we focused on the molecular actions of 243 
sesamin metabolites. We found that SC1, one of sesamin metabolites by CYP450 in vivo, has much 244 
stronger anti-inflammatory activities than sesamin itself in the mouse macrophage-like J774.1 cells. 245 
Our data also showed that the anti-inflammatory effects of SC1 could be attenuated after the phase-246 
II metabolism with the glucuronidation/sulfation of the catechol moieties. These findings indicate 247 
the important role of the catechol groups in the anti-inflammatory effects. However, the activity of 248 
di-catechol SC2 is weaker than that of the mono-catechol SC1, although the detailed actions of 249 
SC2 were not examined in this study. Similarly, the biological activities of quercetin, a 250 
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representative food-derived polyphenol, are generally attenuated after conversion to the 251 
metabolites 36. 252 
After the oral intake of sesamin in humans, sesamin catechols were detected in the β-253 
glucuronidase/sulfatase-treated plasma, but not in the intact plasma 24, indicating that sesamin 254 
catechols are readily metabolized in vivo to the glucuronides and sulfates. Furthermore, the 255 
maximum concentration (Cmax) of SC1 in deconjugation enzyme-treated human plasma was 256 
approximately 18 times higher than that of SC2 24, 25, suggesting that the glucuronides and/or 257 
sulfates of SC1 but not that of SC2 highly contribute to the physiological effects of sesamin in vivo. 258 
Consistent with the reports that macrophages have a β-glucuronidase activity 26-28, SC1 259 
glucuronides were deconjugated to accumulate mainly as SC1m in the macrophages. The cellular 260 
accumulation of SC1 in the cells treated with SC1 glucuronides was also observed in another mouse 261 
macrophage-like cell line, RAW264 (data not shown). The anti-inflammatory activities of SC1 262 
glucuronides significantly increased in a pre-incubation time-dependent manner. The addition of 263 
the β-glucuronidase inhibitor completely cancelled the cellular accumulation of SC1 and SC1m 264 
and anti-inflammatory effects in the cells treated with SC1 glucuronides. In addition, the COMT 265 
inhibitor impaired the cellular accumulation of SC1m with increased SC1 and enhanced the anti-266 
inflammatory effects. These results suggest that sesamin catechol glucuronides are deconjugated 267 
to SC1 by the β-glucuronidase activity and most of SC1 is rapidly converted to SC1m by COMT 268 
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activity, and that SC1 rather than SC1m mainly acts as suppressor of pro-inflammatory signaling 269 
in the cells. 270 
LPS, an outer membrane component of Gram-negative bacteria, can activate the innate 271 
immune system to induce the expression of inflammatory mediators in macrophages/monocytes 37. 272 
The activation of TLR4 by LPS recruits myeloid differentiation protein-88 (MyD88) or toll-273 
interleukin-1 receptor domain-containing adapter inducing IFN-β (TRIF) 38. In the MyD88-274 
dependent pathway, MyD88 activates the downstream signaling components including IκB kinase 275 
β (IKKβ) and MAPK, resulting in the activation of the transcription factor NF-κB and AP-1 to 276 
induce the expression of the pro-inflammatory mediators including iNOS. On the other hand, in 277 
the TRIF-dependent signaling pathway, TRIF activates the IKKε and tumor necrosis factor receptor 278 
associated factor (TRAF) family member associated NF-κB activator-binding kinase1 which 279 
phosphorylates the interferon regulatory factor (IRF3), resulting in the expression of IFN-β 39, 40. 280 
Then, IFN-β stimulates the Janus-activated kinase (JAK) that phosphorylates and activates STAT1 281 
to induce the expression of the downstream genes including iNOS and IP-10 40-42. The activation 282 
of the TRIF pathway also leads to the delayed activation of NF-κB and MAPK mediated through 283 
the association of TRIF with the receptor-interacting protein-1 43.  284 
We found that, consistent with the inhibitory potency against the LPS-induced NO 285 
production, SC1 and SC1 glucuronides suppressed the LPS-induced iNOS expression, whereas the 286 
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LPS-activated MAPK pathway and NF-κB pathway were hardly affected by SC1 and SC1 287 
conjugates, and the LPS-increased IFN-β mRNA expression was significantly suppressed. These 288 
data suggest that SC1 and SC1 glucuronides inhibit the LPS-induced NO production through 289 
attenuation of the IFN-β/iNOS signaling in the TRIF-dependent pathway. As already described, 290 
SC1 could be an active form for the inhibitory effects during the treatment with SC1 glucuronides, 291 
however, the detailed inhibitory mechanisms of SC1 remain unclear. Further investigations are 292 
needed to clarify the upstream targets of SC1 in the LPS-activated TRIF-dependent pathway.  293 
Since the present study aimed to understand the mechanism of action, we employed 10 294 
and 25 μM as the appropriate treatment concentrations of sesamin metabolites to detect their effects 295 
clearly in the in vitro experiments. It has been reported that the hepatic sesamin concentration in 296 
rats at 1 h after 100 mg/kg sesamin administration is 1.1 μM 44. Although much higher levels of 297 
sesamin metabolites than sesamin were detected in rat liver 25, it is unclear whether the 298 
concentration of sesamin metabolites can reach in vivo at the concentrations used in the present 299 
study. Therefore, the further studies on the in vivo concentrations of sesamin metabolites under the 300 
normal and inflammatory conditions are required.  301 
In this study, cells were treated with sesamin metabolites in FBS-free medium, because it 302 
is known that the proteins in FBS such as an albumin bind to the polyphenols to decrease their 303 
bioavailability 45. Therefore, higher level of sesamin metabolites might be required to exhibit the 304 
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biological effects under the condition with the serum compared with under the serum-free condition.  305 
The time-to-maximum concentration Tmax of sesamin metabolites in human plasma is 5 h, 306 
and that sesamin metabolites are detected even at 12-24 h after ingestion of sesamin, though the 307 
concentrations are drastically decreased from Cmax 24. Furthermore, due to the increased β-308 
glucuronidase-like activity at the inflamed sites 26-28, the sesamin metabolites might be 309 
deconjugated to exert the anti-inflammatory effects in vivo in a shorter time than in vitro. Future 310 
efforts should be directed to clarify to what degree the deconjugation-mediated mechanism 311 
contributes to the anti-inflammatory effects of sesamin in vivo. 312 
In conclusion, we demonstrated the anti-inflammatory effects of sesamin metabolites in 313 
mouse macrophage-like J774.1 cells. The scheme for the anti-inflammatory actions of sesamin 314 
metabolites is shown in Figure 6. Sesamin catechol conjugates are considered to be the major 315 
metabolites of sesamin existing in human plasma after the oral ingestion of sesamin 24. Our data 316 
strongly suggested that SC1 glucuronides rather than the sulfates could inhibit the inflammatory 317 
responses through macrophage-mediated deconjugation. Using the COMT inhibitor, we also 318 
demonstrated that SC1 could be an active form for the inhibitory effects in the cell treated with 319 
SC1 glucuronides. These results may explain, at least in part, the molecular mechanisms for the 320 
beneficial health effects of the sesame intake. Our study will provide information for utilization of 321 
natural phenolic compounds, including sesamin, to prevent inflammatory diseases.   322 
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Supporting Information Figure S1. Chromatogram of HPLC-ECD for medium and standards of 342 
sesamin metabolites. 343 
Supporting Information Figure S2. Chromatogram of HPLC-ECD for Figure 3A. The peaks of 344 
chromatogram are identified based on the data in Supporting Information Figure S1. 345 
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chromatogram are identified based on the data in Supporting Information Figure S1. Representative 347 
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FIGURE CAPTIONS 477 
Figure 1. Metabolic pathway of sesamin. (A) CYP450-catalyzed metabolism of sesamin to the 478 
catechol derivatives. (B) Chemical structures of sesamin metabolites used in this study. 479 
 480 
Figure 2. The effects of sesamin-related compounds on the LPS-induced NO production in 481 
macrophages. The J774.1 cells were treated with the combination of each sesamin-related 482 
compound (10 or 25 μM) and LPS (1 μg/mL) for 24 h. After incubation, the nitrite concentration 483 
in the cell culture supernatant was determined by the Griess assay. The data are expressed as 484 
relative values, with LPS only groups being 100%. The values represent the means ± S.D. of three 485 
separate experiments.  486 
 487 
Figure 3. The role of the deconjugation of SC1 conjugates on their anti-inflammatory effects 488 
in macrophages. (A) The J774.1 cells were treated with SC1 conjugates (25 μM) for the indicated 489 
hours. The cellular accumulation of SC1, SC1m and each SC1 conjugate was determined by HPLC-490 
ECD. (B) The J774.1 cells were pre-treated with SC1 conjugates (25 μM) for the indicated hours, 491 
then stimulated by LPS (1 μg/mL) for 24 h. After incubation, the nitrite concentration in the cell 492 
culture supernatant was determined by the Griess assay. The data are expressed as relative values, 493 
with LPS only groups at each treatment time being 100%. The values represent the means ± S.D. 494 
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of three separate experiments. Data were analyzed by a one-way ANOVA followed by Tukey’s 495 
HSD using R software, version 3.4.2. Different letters above the bars indicate significant 496 
differences among treatments for each compound (P<0.05). 497 
 498 
Figure 4. The effects of SC1, SC1m and SC1 conjugates on the LPS-induced proinflammatory 499 
signaling pathway in the macrophages. (A) The J774.1 cells were treated with the combination 500 
of SC1 or SC1m (25 μM) and LPS (1 μg/mL) for 8 h or treated with SC1 conjugates (25 μM) for 501 
24 h prior to the LPS stimulation for 8 h. Whole cell lysates were prepared and a Western blot 502 
analysis was performed for iNOS and β-actin. (B) The J774.1 cells were treated with the 503 
combination of SC1 (25 μM) and LPS (1 μg/mL) for 30 min. Whole cell lysates were prepared and 504 
a Western blot analysis was performed for p-ERK, ERK, p-JNK, JNK, p-p38 MAPK, p38 MAPK, 505 
IκB and β-actin. (C) The J774.1 cells were treated with SC1 conjugates (25 μM) for 24 h prior to 506 
LPS stimulation for 30 min. Whole cell lysates were prepared and a Western blot analysis was 507 
performed for p-ERK, ERK, p-JNK, JNK, p-p38 MAPK, p38 MAPK, IκB and β-actin. (D) The 508 
J774.1 cells were treated with the combination of SC1 (25 μM) and LPS (1 μg/mL) for 3 h or 509 
treated with SC1 conjugates (25 μM) for 24 h prior to LPS stimulation for 3 h. The relative mRNA 510 
level of IFN-β normalized to GAPDH was determined by a real-time RT-PCR. The values represent 511 
the means ± S.D. of three separate experiments. Data were analyzed by a one-way ANOVA 512 
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followed by Tukey’s HSD using R software, version 3.4.2. Different letters above the bars indicate 513 
significant differences among treatments for each compound (P<0.05). 514 
 515 
Figure 5. The effects of β-glucuronidase inhibitor and COMT inhibitor on the cellular 516 
accumulation of SC1 and SC1m and the anti-inflammatory effects induced by the treatment 517 
of SC1 glucuronides in the macrophages. (A) Cells were treated with SC1 conjugates (25 μM) 518 
in the absence and presence of D-saccharic acid 1,4-lactone (2 mM) for 24 h. D-Saccharic acid 1,4-519 
lactone was added to the medium every 8 h to maintain the activity due to its instability. The cellular 520 
accumulation of SC1m and SC1 were determined by HPLC-ECD. (B) The J774.1 cells were pre-521 
treated with SC1 conjugates (25 μM) for 24 h in the absence and presence of D-saccharic acid 1,4-522 
lactone (2 mM). D-Saccharic acid 1,4-lactone was added to the medium every 8 h to maintain the 523 
activity due to its instability. The cells were then stimulated by LPS (1 μg/mL) for 24 h and the 524 
nitrite concentration in the cell culture supernatant was determined by a Griess assay. (C) The 525 
J774.1 cells were pre-treated with SC1 conjugates (25 μM) for 24 h in the absence and presence of 526 
3,5-dinitrocatechol (5 μM). The cells were then stimulated by LPS (1 μg/mL) for 24 h and the 527 
nitrite concentration in the cell culture supernatant was determined by a Griess assay. The values 528 
represent the means ± S.D. of three separate experiments. Data were analyzed by a one-way 529 
ANOVA followed by Tukey’s HSD using R software, version 3.4.2. Different letters above the bars 530 
32 
 
indicate significant differences among treatments for each compound (P<0.05). 531 
 532 
Figure 6. Proposed mechanism for the anti-inflammation by SC1 conjugates. Sesamin is 533 
converted by the phase-I metabolism into catechol derivatives and further converted by a phase-II 534 
metabolism into their glucuronide or sulfate conjugates in vivo. SC1 glucuronides are deconjugated 535 
to accumulate in the cells mainly as SC1m due to the β-glucuronidase activity and the COMT 536 
activity of macrophage. On the other hand, SC1 sulfates are scarcely deconjugated. Pre-treatment 537 
of SC1 glucuronides inhibit LPS-induced NO production through attenuation of the IFN-β/iNOS 538 
signaling in the TRIF-dependent pathway, but not in the MyD88-dependent pathway. SC1 rather 539 
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